Evoke Pharma's stock soared 90% on Monday due to positive results of its nasal medicine, Gimoti, for diabetic gastroparesis. The study compared healthcare resource use for Gimoti and oral metoclopramide, highlighting the benefit of nasal delivery for patients with stomach paralysis.